CervoMed (NASDAQ:CRVO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

Several other research analysts have also recently weighed in on the company. Roth Capital set a $9.00 price objective on CervoMed in a research report on Monday, May 18th. Chardan Capital boosted their target price on shares of CervoMed from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research note on Monday, April 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $31.00 price target on shares of CervoMed in a research report on Wednesday, April 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.60.

CervoMed Trading Down 0.3%

CervoMed stock opened at $3.07 on Wednesday. The company has a market capitalization of $41.52 million, a price-to-earnings ratio of -0.94 and a beta of -0.68. CervoMed has a 12 month low of $2.13 and a 12 month high of $13.13. The stock’s 50 day moving average is $3.33 and its 200-day moving average is $4.44.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%. As a group, equities research analysts predict that CervoMed will post -2.84 earnings per share for the current fiscal year.

Insider Activity

In other CervoMed news, Director Joshua S. Boger purchased 955,414 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $3.14 per share, with a total value of $2,999,999.96. Following the acquisition, the director owned 1,795,865 shares of the company’s stock, valued at approximately $5,639,016.10. This represents a 113.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 35.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in shares of CervoMed by 8,425,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock valued at $666,000 after purchasing an additional 84,259 shares during the last quarter. Jane Street Group LLC bought a new position in CervoMed in the 2nd quarter valued at approximately $414,000. Renaissance Technologies LLC acquired a new stake in CervoMed in the first quarter valued at approximately $252,000. Byrne Asset Management LLC boosted its position in CervoMed by 248.6% in the second quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock valued at $159,000 after buying an additional 36,550 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of CervoMed during the third quarter worth $247,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.